US20230310371A1 - Agent for reducing amount of amyloid b protein - Google Patents
Agent for reducing amount of amyloid b protein Download PDFInfo
- Publication number
- US20230310371A1 US20230310371A1 US18/116,914 US202318116914A US2023310371A1 US 20230310371 A1 US20230310371 A1 US 20230310371A1 US 202318116914 A US202318116914 A US 202318116914A US 2023310371 A1 US2023310371 A1 US 2023310371A1
- Authority
- US
- United States
- Prior art keywords
- agent
- amount
- compound
- brain
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004169 proteins and genes Human genes 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 210000004556 brain Anatomy 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 11
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 10
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 10
- HQNACSFBDBYLJP-UHFFFAOYSA-N 1-[3-[2-(1-benzothiophen-5-yl)ethoxy]propyl]azetidin-3-ol Chemical compound C1C(O)CN1CCCOCCC1=CC=C(SC=C2)C2=C1 HQNACSFBDBYLJP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 26
- 230000002829 reductive effect Effects 0.000 claims description 5
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 55
- 239000003795 chemical substances by application Substances 0.000 abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- 229940126062 Compound A Drugs 0.000 description 34
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 34
- 239000003826 tablet Substances 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000011812 mixed powder Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 230000003920 cognitive function Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960003135 donepezil hydrochloride Drugs 0.000 description 4
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000004203 carnauba wax Substances 0.000 description 3
- 235000013869 carnauba wax Nutrition 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- -1 nitrogen-containing organic base Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940078389 rivastigmine transdermal system Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonic acid Chemical compound CC1=CC(C)=C(S(O)(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- USUHXXKCHSBMOS-XPSHAMGMSA-N galanthamine hydrochloride Chemical compound Cl.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 USUHXXKCHSBMOS-XPSHAMGMSA-N 0.000 description 1
- 150000004677 hydrates Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003125 hypromellose 2910 Polymers 0.000 description 1
- 229940031672 hypromellose 2910 Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000967 memantine hydrochloride Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007138 neurofibrillary change Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960004323 rivastigmine tartrate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012453 solvate Chemical group 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003565 tacrine hydrochloride Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to an agent for reducing the amount of amyloid ⁇ protein, comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient.
- Dementia is a neurodegenerative disease with significantly reduced cognitive function caused by, for example, brain atrophy and/or cerebrovascular disorder. Dementia is classified into some types by its cause, and 60% to 80% of the patients with dementia suffers from Alzheimer’s disease (AD) (Non Patent Literature 1). The pathogenesis of AD is complicated, and the cause is considered to be the formation of senile plaques due to coagulation of amyloid- ⁇ protein (A ⁇ ) or neurofibrillary changes caused by coagulation of phosphorylated Tau protein (p-Tau) (Non Patent Literature 2). The number of patients with AD in Japan is estimated to be about more than 1,160,000.
- Non Patent Literatures 3, 4 The incidence is higher in advanced age, and thus with the aging of society, the number of patients is expected to increase rapidly, causing a greater burden on patients’ family and a sharp rise in medical and nursing care expenses in the future (Non Patent Literatures 3, 4). Thus, treatment of AD is important for not only preventing patients’ quality of life from decreasing and reducing burden on their family thereafter, but also reducing medical expenses in the future aging society.
- Symptoms of dementia include core symptoms of cognitive impairment and peripheral symptoms such as problem behaviors seen when patients with cognitive impairment interact with people around them (Non Patent Literature 5).
- agents are used as an agent for treating AD in Japan: donepezil hydrochloride, galantamine hydrobromide, and rivastigmine, which are acetylcholinesterase inhibitors, and memantine hydrochloride which is a N-methyl-D-aspartate receptor antagonist. These are all capable of reducing core symptoms or peripheral symptoms.
- these drugs are symptomatic drugs which improve core symptoms or peripheral symptoms for a certain period of time, and do not suppress neurodegeneration in AD. Although these drugs are temporally effective in improving cognitive function at the beginning of use, the cognitive function usually becomes worse than cognitive function before the treatment, after about 48 weeks or more (Non Patent Literature 6).
- a ⁇ The amount of A ⁇ , which is considered to cause the development of AD, is known to be controlled by its production by cleavage of precursor protein and its removal by glial cells in the brain.
- a ⁇ is known to accumulate in the brain with age as a soluble oligomer or insoluble aggregate. Soluble A ⁇ in the brain is incorporated into astrocytes and microglia.
- a ⁇ which has become insoluble and been aggregated is phagocytosed by microglia expressing complement receptor and IgG receptor, and excreted into cerebrospinal fluid (CSF), lymph or blood (Non-patent Literature 7).
- CSF cerebrospinal fluid
- lymph or blood Non-patent Literature 7
- Non-patent Literature 9 A literature on diagnostic criteria of AD describes a reduced amount of A ⁇ in CSF and an increased accumulation of amyloid tracer in PET imaging as a biomarker of deposition of A ⁇ in the brain (Non-patent Literature 9).
- Compound A 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol (hereinafter referred to as “Compound A”) or a salt thereof is known to have neuroprotective, nerve regeneration-promoting and neurite outgrowth actions, and be useful as a therapeutic agent for central and peripheral neurological diseases (Patent Literature 1). Furthermore, a publication discloses that usually the drug may be administered to an adult in a dose or divided doses of 0.01 to 500 mg per day (Patent Literature 2).
- An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of A ⁇ in the brain is increased, such as AD.
- Compound A or a salt thereof has an effect of increasing the amount of A ⁇ in CSF, in other word, an effect of reducing the amount of A ⁇ in the brain parenchyma, and the present invention has been completed.
- the present invention provides the following.
- An agent for reducing the amount of A ⁇ in the brain comprising Compound A or a salt thereof as an active ingredient.
- the agent for reducing the amount of A ⁇ according to any one of (1) to (4), wherein the agent is for administration to a patient with a disease in which the amount of A ⁇ in the brain is increased.
- the agent for reducing the amount of A ⁇ according to any one of (1) to (4), wherein the agent is for administration to a patient with AD, Probable AD, Possible AD, Preclinical AD, Prodromal AD, mild cognitive impairment due to AD (MCI due to ADI) or MCI.
- agent for reducing the amount of A ⁇ according to any one of (1) to (4), wherein the agent is for administration to a patient with AD, MCI due to AD or MCI.
- the present invention also provides the following.
- the amount of A ⁇ in CSF can be increased and the amount of A ⁇ in the brain parenchyma can be reduced by administering Compound A or a salt thereof, and thus a disease in which the amount of A ⁇ in the brain is increased, such as AD, can be prevented or treated.
- FIG. 1 is a graph showing change in the concentration of A ⁇ (A ⁇ -38, A ⁇ -40 and A ⁇ -42) in cerebrospinal fluid at week 52 from the baseline. “n.s.” means that there was no statistically significant difference.
- the numerical range shown with “to” represents a range inclusive of the value before and after “to” as the minimum and maximum value, respectively.
- Compound A means 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol.
- Examples of salts of Compound A include known salts of a basic group such as amino group or an acidic group such as hydroxyl group or carboxyl group.
- salts of a basic group include salts with a mineral acid such as hydrochloric acid, hydrogen bromide, nitric acid and sulfuric acid; salts with an organic carboxylic acid such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with a sulfonic acid such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid.
- a mineral acid such as hydrochloric acid, hydrogen bromide, nitric acid and sulfuric acid
- salts with an organic carboxylic acid such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succ
- salts of an acidic group include salts with an alkali metal such as sodium and potassium; salts with an alkaline earth metal such as calcium and magnesium; ammonium salts; and salts with a nitrogen-containing organic base such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-efenamin and N,N′-dibenzylethylenediamine.
- an alkali metal such as sodium and potassium
- salts with an alkaline earth metal such as calcium and magnesium
- ammonium salts and salts with a nitrogen-containing organic base
- a nitrogen-containing organic base such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N
- salts with maleic acid are preferred.
- Compound A or a salt thereof has isomers (e.g., optical isomers, geometric isomers and tautomers)
- the present invention includes all these isomers and also includes hydrates, solvates and any crystal forms thereof.
- Examples of diseases in which the amount of A ⁇ in the brain is increased include AD, Probable AD, Possible AD, Preclinical AD, Prodromal AD, MCI due to AD, MCI and Down syndrome.
- examples preferably include AD, Probable AD, Possible AD, Preclinical AD, Prodromal AD, MCI due to AD and MCI, more preferably AD, MCI due to AD and MCI, and further preferably AD and MCI due to AD.
- AD Alzheimer’s Dement., May 2011, Vol. 7, No. 3, pp. 263 - 292.
- Prevention means to prevent the onset of a specific disease or at least one symptom caused by the disease.
- Treatment means to reduce or improve at least one symptom caused by a specific disease with which a subject is affected, and delay the progress of the disease.
- prevention means to inhibit or delay the onset or progress of increase in the amount of insoluble A ⁇ in the brain in a patient with, for example, AD.
- Treatment means to inhibit or delay the progress of increase in the amount of insoluble A ⁇ in the brain or to reduce the amount of insoluble A ⁇ in the brain.
- NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer’s Disease and Related Disorders Associations
- a usual doctor may reasonably make clinical diagnosis of “mild to moderate Alzheimer’s disease” using standard criteria.
- MMSE Mini-Mental State Examination
- scores of 0 to 30 clinical diagnosis of mild to moderate, moderate, or moderate to severe AD is provided.
- the MMSE (Folstein, Folstein and McHugh, 1975) is a simple test of cognitive function including an interview with patients. Orientation, memory, calculation and attention, language skills and other functions are assessed. The total score is 30. The lower the score, the higher the level of impairment of cognitive function.
- CSF cerebrospinal fluid
- Compound A or a salt thereof used in the present invention may be prepared by a method known per se or by combining such methods, or by the method disclosed in Patent Literature 1.
- Compound A or a salt thereof used in the present invention may be blended with various pharmaceutical additives such as an excipient, a binding agent, a disintegrating agent, a disintegration inhibitor, a consolidation/adhesion-preventing agent, a lubricant, an absorption/adsorption carrier, a solvent, a bulking agent, an isotonic agent, a solubilizer, an emulsifier, a suspending agent, a thickener, a coating agent, an absorption enhancer, a gelling/procoagulant agent, a light stabilizer, a preservative, a desiccant, an emulsification/suspension/dispersion stabilizer, a color protecting agent, a deoxidant/antioxidant, a flavoring agent, a coloring agent, a foaming agent, an antifoaming agent, a soothing agent, an antistatic agent, a buffer, and/or a pH adjuster to give a pharmaceutical preparation such as an oral preparation (e.g.
- the above agents are formulated by a usual method.
- the method of administration of Compound A which is not particularly limited, is accordingly determined based on the form of the preparation, the age, sex and other conditions of the patient and the level of symptoms of the patient.
- the dose of Compound A is accordingly selected based on the administration, the age, sex, type of disease and other conditions of the patient.
- the agent may be administered to an adult in a dose or divided doses of usually 40 to 500 mg in terms of Compound A per day.
- the agent is administered in a dose or divided doses of preferably 100 to 400 mg in terms of Compound A per day, and administered in a dose of further preferably 160 mg or 320 mg in terms of Compound A per day.
- AchEIs acetylcholinesterase inhibitors
- AchEIs include donepezil hydrochloride, galantamine hydrochloride, rivastigmine tartrate and tacrine hydrochloride.
- the subject may have undergone prevention or treatment by administration of AChEI for at least 6 months before administration of Compound A or a salt thereof.
- Test Example 1 Multicenter randomized double-blind phase II placebo-controlled trial for assessing effectiveness and safety of Compound A in mild to moderate AD patients
- Subject selection criteria: Patients were screened in a period from 42 days before treatment assignment to the assignment based on the following selection criteria.
- Cerebrospinal fluid was collected by lumber puncture from subjects at baseline (within 2 weeks before the first day of administration of investigational drug) and after 52 weeks (within 2 weeks before week 52), and divided into 9-ml aliquots in polyethylene tubes and stored at -80° C.
- the A ⁇ -42 value in the cerebrospinal fluid was measured by sandwich ELIZA which has been designed for measurement of A ⁇ including 1 amino acid and 42 amino acids.
- CSF cerebrospinal fluid
- CSF cerebrospinal fluid
- the concentration of A ⁇ tended to be increased in a dose dependent manner in the Compound A group compared to the placebo group.
- magnesium stearate magnesium stearate, Merck
- TF-LABO roller pressure 3 MPa
- Freund Corporation Freund Corporation
- lactose (FlowLac 90, Meggle Japan)
- 16.50 g of crystalline cellulose CEOLUS PH302, Asahi Kasei Chemicals
- 6.67 g of croscarmellose sodium (Primellose, DMV Japan) were each sieved through a sieve with an opening of 850 ⁇ m and added to 60.0 g of the resulting granulated powder, and the mixture was mixed for 10 minutes.
- 0.6667 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 30 minutes.
- the mixed powder was tableted by a tableting machine (HT-P18A, Hata Tekkosho) at a tableting pressure of about 12 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 250 mg.
- the uncoated tablets were coated with 8 mg of a coating agent per tablet using a film coater DRC-200 (Powrex), and then a small amount of carnauba wax (Polishing Wax-105, Nippon Wax) was added thereto to give film-coated tablets.
- mannitol Parteck M200, Merck
- 3.60 g croscarmellose sodium were added to 53.70 g of maleate of Compound A and the mixture was mixed for 10 minutes.
- 1.80 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 30 minutes.
- the mixed powder was tableted at a tableting pressure of about 10 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 250 mg.
- the uncoated tablets were coated with 8 mg of a coating agent (Opadry 03F44057, 00F440000 (hypromellose 2910: 71.5%, Macrogol 6000: 14.166%, talc: 7.167%, titanium oxide: 7.067%, iron sesquioxide: 0.1%), Colorcon Japan LLC) per tablet, and then a small amount of carnauba wax was added thereto to give film-coated tablets.
- a coating agent Opadry 03F44057, 00F440000 (hypromellose 2910: 71.5%, Macrogol 6000: 14.166%, talc: 7.167%, titanium oxide: 7.067%, iron sesquioxide: 0.1%), Colorcon Japan LLC
- magnesium stearate 0.90 g was added to the mixed powder and the mixture was mixed for 5 minutes.
- the mixed powder was tableted at a tableting pressure of about 7 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 315 mg.
- the uncoated tablets were coated with 9 mg of a coating agent per tablet, and then a small amount of carnauba wax was added thereto to give film-coated tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of amyloid β protein in the brain is increased, such as Alzheimer’s disease. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of amyloid β protein in the brain parenchyma, and thus is effective as an agent for reducing the amount of amyloid β protein in the brain. Disease in which the amount of amyloid β protein in the brain is increased, such as Alzheimer’s disease, can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
Description
- This application is a continuation of Application No. 16/617,607 filed Nov. 27, 2019, which is a National Stage of Application No. PCT/JP2018/021226 filed Jun. 1, 2018, claiming priority based on Japanese Patent Application No. 2017-109886 filed Jun. 2, 2017 and Japanese Patent Application No. 2017-128474 filed Jun. 30, 2017.
- The present invention relates to an agent for reducing the amount of amyloid β protein, comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient.
- Dementia is a neurodegenerative disease with significantly reduced cognitive function caused by, for example, brain atrophy and/or cerebrovascular disorder. Dementia is classified into some types by its cause, and 60% to 80% of the patients with dementia suffers from Alzheimer’s disease (AD) (Non Patent Literature 1). The pathogenesis of AD is complicated, and the cause is considered to be the formation of senile plaques due to coagulation of amyloid-β protein (Aβ) or neurofibrillary changes caused by coagulation of phosphorylated Tau protein (p-Tau) (Non Patent Literature 2). The number of patients with AD in Japan is estimated to be about more than 1,160,000. The incidence is higher in advanced age, and thus with the aging of society, the number of patients is expected to increase rapidly, causing a greater burden on patients’ family and a sharp rise in medical and nursing care expenses in the future (Non Patent Literatures 3, 4). Thus, treatment of AD is important for not only preventing patients’ quality of life from decreasing and reducing burden on their family thereafter, but also reducing medical expenses in the future aging society.
- Symptoms of dementia include core symptoms of cognitive impairment and peripheral symptoms such as problem behaviors seen when patients with cognitive impairment interact with people around them (Non Patent Literature 5). At present four agents are used as an agent for treating AD in Japan: donepezil hydrochloride, galantamine hydrobromide, and rivastigmine, which are acetylcholinesterase inhibitors, and memantine hydrochloride which is a N-methyl-D-aspartate receptor antagonist. These are all capable of reducing core symptoms or peripheral symptoms. However, these drugs are symptomatic drugs which improve core symptoms or peripheral symptoms for a certain period of time, and do not suppress neurodegeneration in AD. Although these drugs are temporally effective in improving cognitive function at the beginning of use, the cognitive function usually becomes worse than cognitive function before the treatment, after about 48 weeks or more (Non Patent Literature 6).
- The amount of Aβ, which is considered to cause the development of AD, is known to be controlled by its production by cleavage of precursor protein and its removal by glial cells in the brain. Aβ is known to accumulate in the brain with age as a soluble oligomer or insoluble aggregate. Soluble Aβ in the brain is incorporated into astrocytes and microglia. On the other hand, Aβ which has become insoluble and been aggregated is phagocytosed by microglia expressing complement receptor and IgG receptor, and excreted into cerebrospinal fluid (CSF), lymph or blood (Non-patent Literature 7). The amount of Aβ in CSF is decreased with the progress of AD (Non-patent Literature 8). This is thought to suggest an increased amount of aggregated Aβ in the brain. A literature on diagnostic criteria of AD describes a reduced amount of Aβ in CSF and an increased accumulation of amyloid tracer in PET imaging as a biomarker of deposition of Aβ in the brain (Non-patent Literature 9).
- 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol (hereinafter referred to as “Compound A”) or a salt thereof is known to have neuroprotective, nerve regeneration-promoting and neurite outgrowth actions, and be useful as a therapeutic agent for central and peripheral neurological diseases (Patent Literature 1). Furthermore, a publication discloses that usually the drug may be administered to an adult in a dose or divided doses of 0.01 to 500 mg per day (Patent Literature 2).
-
- Patent Literature 1: International Publication No. WO 2003/035647
- Patent Literature 2: International Publication No. WO 2003/105830
-
- Non Patent Literature 1: 2012 Alzheimer’s Disease Facts and Figures. (http://www.alz.org/downloads/facts figures 2012.pdf)
- Non Patent Literature 2: YAKUGAKU ZASSHI, 2010, Vol. 130, No. 4, pp. 521-526
- Non Patent Literature 3: Japanese Journal of Clinical Medicine, 2008, Vol. 66 (Extra ed. 1), pp. 23-27
- Non Patent Literature 4: Press Release by Seed Planning (Dec. 28, 2010) (http://www.seedplanning.co.jp/press/2010/2010122801.html)
- Non Patent Literature 5: Japanese Journal of Clinical Psychopharmacology, 2011, Vol. 14, No. 7, pp. 1123-1129
- Non Patent Literature 6: Japanese Journal of Clinical Psychopharmacology, 2012, Vol. 15, No. 3, pp. 311-321
- Non-patent Literature 7: Proceedings of the Annual Meeting of the Japanese Research Group on Senile Dementia, 2010, Vol. 15, pp. 79-81
- Non-patent Literature 8: Archives of Neurology, 2011, Vol. 68, No. 10, pp. 1257-1266
- Non-patent Literature 9: Japanese Journal of Geriatrics, 2013, Vol. 50, No. 1, pp. 1-8
- Drugs which suppress progress of AD by inhibiting neurodegeneration need to be developed early. An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of Aβ in the brain is increased, such as AD.
- In such circumstances, the present inventors have found that Compound A or a salt thereof has an effect of increasing the amount of Aβ in CSF, in other word, an effect of reducing the amount of Aβ in the brain parenchyma, and the present invention has been completed.
- The present invention provides the following.
- An agent for reducing the amount of Aβ in the brain, comprising Compound A or a salt thereof as an active ingredient.
- The agent for reducing the amount of Aβ according to (1), wherein the amount of Aβ in the brain is reduced by increasing the amount of Aβ in CSF.
- The agent for reducing the amount of Aβ according to (1) or (2), wherein the agent is orally administered in a dose of 100 mg to 400 mg in terms of Compound A once a day.
- The agent for reducing the amount of Aβ according to (1) or (2), wherein the agent is orally administered in a dose of 160 mg or 320 mg in terms of Compound A once a day.
- The agent for reducing the amount of Aβ according to any one of (1) to (4), wherein the agent is for administration to a patient with a disease in which the amount of Aβ in the brain is increased.
- The agent for reducing the amount of Aβ according to any one of (1) to (4), wherein the agent is for administration to a patient with AD, Probable AD, Possible AD, Preclinical AD, Prodromal AD, mild cognitive impairment due to AD (MCI due to ADI) or MCI.
- The agent for reducing the amount of Aβ according to any one of (1) to (4), wherein the agent is for administration to a patient with AD, MCI due to AD or MCI.
- The present invention also provides the following.
- (a) An agent for increasing the amount of Aβ in CSF, comprising Compound A or a salt thereof as an active ingredient.
- (b) Compound A or a salt thereof for use in a therapeutic measure for reducing the amount of Aβ in the brain.
- (c) Compound A or a salt thereof for use in a therapeutic measure for increasing the amount of Aβ in CSF.
- (d) A method of reducing the amount of Aβ in the brain, comprising administering Compound A or a salt thereof to a patient.
- (e) A method of increasing the amount of Aβ in CSF, comprising administering Compound A or a salt thereof to a patient.
- (f) Use of Compound A or a salt thereof for producing an agent for reducing the amount of Aβ in the brain.
- (g) Use of Compound A or a salt thereof for producing an agent for increasing the amount of Aβ in CSF.
- The amount of Aβ in CSF can be increased and the amount of Aβ in the brain parenchyma can be reduced by administering Compound A or a salt thereof, and thus a disease in which the amount of Aβ in the brain is increased, such as AD, can be prevented or treated.
- [
FIG. 1 ]FIG. 1 is a graph showing change in the concentration of Aβ (Aβ-38, Aβ-40 and Aβ-42) in cerebrospinal fluid at week 52 from the baseline. “n.s.” means that there was no statistically significant difference. - Hereinafter the present invention will be described in detail.
- In the present description, the respective terms have the following meaning unless otherwise specified.
- In the present description, the numerical range shown with “to” represents a range inclusive of the value before and after “to” as the minimum and maximum value, respectively.
- Compound A means 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol.
- Examples of salts of Compound A include known salts of a basic group such as amino group or an acidic group such as hydroxyl group or carboxyl group.
- Examples of salts of a basic group include salts with a mineral acid such as hydrochloric acid, hydrogen bromide, nitric acid and sulfuric acid; salts with an organic carboxylic acid such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with a sulfonic acid such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid.
- Examples of salts of an acidic group include salts with an alkali metal such as sodium and potassium; salts with an alkaline earth metal such as calcium and magnesium; ammonium salts; and salts with a nitrogen-containing organic base such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-efenamin and N,N′-dibenzylethylenediamine.
- Of the above salts, pharmacologically acceptable salts are preferred, and salts with maleic acid are more preferred.
- In the case where Compound A or a salt thereof has isomers (e.g., optical isomers, geometric isomers and tautomers), the present invention includes all these isomers and also includes hydrates, solvates and any crystal forms thereof.
- Examples of diseases in which the amount of Aβ in the brain is increased include AD, Probable AD, Possible AD, Preclinical AD, Prodromal AD, MCI due to AD, MCI and Down syndrome.
- In an embodiment of the invention, examples preferably include AD, Probable AD, Possible AD, Preclinical AD, Prodromal AD, MCI due to AD and MCI, more preferably AD, MCI due to AD and MCI, and further preferably AD and MCI due to AD.
- Diagnosis of AD is described in Alzheimer’s Dement., May 2011, Vol. 7, No. 3, pp. 263 - 292.
- Prevention means to prevent the onset of a specific disease or at least one symptom caused by the disease.
- Treatment means to reduce or improve at least one symptom caused by a specific disease with which a subject is affected, and delay the progress of the disease.
- In an embodiment of the present invention, prevention means to inhibit or delay the onset or progress of increase in the amount of insoluble Aβ in the brain in a patient with, for example, AD. Treatment means to inhibit or delay the progress of increase in the amount of insoluble Aβ in the brain or to reduce the amount of insoluble Aβ in the brain.
- Mild to moderate Alzheimer’s disease may be clinically diagnosed as “probable AD” according to the diagnosis criteria provided by the National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer’s Disease and Related Disorders Associations (NINCDS-ADRDA).
- A usual doctor may reasonably make clinical diagnosis of “mild to moderate Alzheimer’s disease” using standard criteria. For example, according to the score of the standardized Mini-Mental State Examination (MMSE, scores of 0 to 30), clinical diagnosis of mild to moderate, moderate, or moderate to severe AD is provided. The MMSE (Folstein, Folstein and McHugh, 1975) is a simple test of cognitive function including an interview with patients. Orientation, memory, calculation and attention, language skills and other functions are assessed. The total score is 30. The lower the score, the higher the level of impairment of cognitive function.
- In Test Examples of the present invention, patients with an MMSE score of 12 to 22 at the start of the test (screening) were determined as mild to moderate AD. Note that the MMSE is not the only way to clinically determine the grade of AD, though convenient.
- The relationship between cerebrospinal fluid (CSF) biomarkers and conditions of AD is widely studied. Amyloid β protein (Aβ-38, Aβ-40 and Aβ-42) in CSF may reflect the level of deposition of amyloid in the brain. Change in Aβ may indicate the effect of a drug for metabolism, deposition or elimination of Aβ.
- Compound A or a salt thereof used in the present invention may be prepared by a method known per se or by combining such methods, or by the method disclosed in Patent Literature 1.
- Compound A or a salt thereof used in the present invention may be blended with various pharmaceutical additives such as an excipient, a binding agent, a disintegrating agent, a disintegration inhibitor, a consolidation/adhesion-preventing agent, a lubricant, an absorption/adsorption carrier, a solvent, a bulking agent, an isotonic agent, a solubilizer, an emulsifier, a suspending agent, a thickener, a coating agent, an absorption enhancer, a gelling/procoagulant agent, a light stabilizer, a preservative, a desiccant, an emulsification/suspension/dispersion stabilizer, a color protecting agent, a deoxidant/antioxidant, a flavoring agent, a coloring agent, a foaming agent, an antifoaming agent, a soothing agent, an antistatic agent, a buffer, and/or a pH adjuster to give a pharmaceutical preparation such as an oral preparation (e.g., tablets, capsules, powders, granules, fine granules, pills, suspensions, emulsions, liquids, and syrups), injections, eye drops, nasal sprays and transdermal agents. Tablets are preferred as an oral dosage form for patients with AD.
- The above agents are formulated by a usual method.
- The method of administration of Compound A, which is not particularly limited, is accordingly determined based on the form of the preparation, the age, sex and other conditions of the patient and the level of symptoms of the patient.
- The dose of Compound A is accordingly selected based on the administration, the age, sex, type of disease and other conditions of the patient.
- The agent may be administered to an adult in a dose or divided doses of usually 40 to 500 mg in terms of Compound A per day. The agent is administered in a dose or divided doses of preferably 100 to 400 mg in terms of Compound A per day, and administered in a dose of further preferably 160 mg or 320 mg in terms of Compound A per day.
- In the administration of Compound A or a salt thereof in the present invention, prevention or treatment by administration of acetylcholinesterase inhibitors (AChEIs) may also be included. Examples of AchEIs include donepezil hydrochloride, galantamine hydrochloride, rivastigmine tartrate and tacrine hydrochloride.
- In the present invention, the subject may have undergone prevention or treatment by administration of AChEI for at least 6 months before administration of Compound A or a salt thereof.
- Next, the present invention will be described with reference to Test Examples and Preparation Examples, but the present invention is not limited thereto.
- Maleate of Compound A was used as the test compound.
- Test Example 1 Multicenter randomized double-blind phase II placebo-controlled trial for assessing effectiveness and safety of Compound A in mild to moderate AD patients Subject (selection criteria): Patients were screened in a period from 42 days before treatment assignment to the assignment based on the following selection criteria.
- Patients who were probable AD and are 55 years old or older and 85 years old or younger at the time of obtaining consent of screening.
- Patients with an MMSE score of 12 to 22 at the time of screening
- Patients with a Modified Hachinski Ischemia Scale score of 4 or less
- Patients who have been treated with a donepezil hydrochloride or rivastigmine transdermal system for at least 4 months before the baseline and with a stable dose thereof for 3 months before the baseline.
- In the case of patients who have received memantine in addition to being treated with a donepezil hydrochloride or rivastigmine transdermal system, patients who have been treated with memantine for at least 4 months before the baseline and with a stable dose thereof for 3 months before the baseline.
- Patients whose brain MRI or CT results match AD at the time of screening
- Organization of groups: Patients matched (484 patients) were randomly divided into the following 3 groups and the trial was started.
- (1) High dose group: 224 mg of a test compound (160 mg in terms of Compound A) was orally administered once a day for 4 weeks and then 448 mg of a test compound (320 mg in terms of Compound A) was orally administered once a day for 48 weeks (158 patients)
- (2) Low dose group: 224 mg of a test compound (160 mg in terms of Compound A) was orally administered once a day for 52 weeks (166 patients)
- (3) Placebo group: placebo was orally administered once a day for 52 weeks (158 patients) Method of assessment:
- Cerebrospinal fluid was collected by lumber puncture from subjects at baseline (within 2 weeks before the first day of administration of investigational drug) and after 52 weeks (within 2 weeks before week 52), and divided into 9-ml aliquots in polyethylene tubes and stored at -80° C. The Aβ-42 value in the cerebrospinal fluid was measured by sandwich ELIZA which has been designed for measurement of Aβ including 1 amino acid and 42 amino acids.
- Change in cerebrospinal fluid (CSF) biomarkers at week 52 from the baseline was compared by analysis of covariance between a high dose group and a placebo group, and between a low dose group and the placebo group. For models, the baseline of cerebrospinal fluid (CSF) biomarkers was included as a covariate and the significance level was 5%. Results: shown below
- Change in the concentration of cerebrospinal fluid (CSF) biomarkers (Aβ-38, Aβ-40, Aβ-42) at week 52 from the baseline is shown in Table 1 and
FIG. 1 . -
[TABLE 1] Group Number of cases/ statistics Biomarker Aβ-38(pg/mL) Aβ-40(pg/mL) Aβ-42(pg/mL) High dose group Number of cases 24 24 24 Least square means (standard error) 178.64(221.978) 290.84(466.956) 11.55(25.578) Difference from placebo group (95% Confidence interval) 525.66 (-157.19, 1208.50) 1206.87 (-236.41, 2650.16) 32.90 (-45.62, 111.41) p-value 0.1286 0.0995 0.4047 Low dose group Number of cases 17 17 17 Least square means (standard error) -219.58(266.774) -840.32(559.467) -9.70(30.362) Difference from placebo group (95% Confidence interval) 127.43 (-625.01, 879.87) 75.71 (-1507.58, 1659.00) 11.65 (-73.37, 96.67) p-value 0.7356 0.9240 0.7847 Placebo group Number of cases 18 18 18 Least square means (standard error) -347.01(258.755) -916.03(546.085) -21.35(29.584) - For the change in the concentration of Aβ in the cerebrospinal fluid at week 52 from the baseline, the concentration of Aβ tended to be increased in a dose dependent manner in the Compound A group compared to the placebo group.
- 0.9726 g of magnesium stearate (magnesium stearate, Merck) was added to 174.03 g of maleate of Compound A and the mixture was mixed for 30 minutes. The mixed powder was compression-molded by a roller compactor (TF-LABO (roll pressure 3 MPa), Freund Corporation), and the solid obtained by molding was granulated. 49.51 g of lactose (FlowLac 90, Meggle Japan), 16.50 g of crystalline cellulose (CEOLUS PH302, Asahi Kasei Chemicals) and 6.67 g of croscarmellose sodium (Primellose, DMV Japan) were each sieved through a sieve with an opening of 850 µm and added to 60.0 g of the resulting granulated powder, and the mixture was mixed for 10 minutes. 0.6667 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 30 minutes. The mixed powder was tableted by a tableting machine (HT-P18A, Hata Tekkosho) at a tableting pressure of about 12 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 250 mg. The uncoated tablets were coated with 8 mg of a coating agent per tablet using a film coater DRC-200 (Powrex), and then a small amount of carnauba wax (Polishing Wax-105, Nippon Wax) was added thereto to give film-coated tablets.
- 60.90 g of mannitol (Parteck M200, Merck) and 3.60 g croscarmellose sodium were added to 53.70 g of maleate of Compound A and the mixture was mixed for 10 minutes. 1.80 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 30 minutes. The mixed powder was tableted at a tableting pressure of about 10 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 250 mg. The uncoated tablets were coated with 8 mg of a coating agent (Opadry 03F44057, 00F440000 (hypromellose 2910: 71.5%, Macrogol 6000: 14.166%, talc: 7.167%, titanium oxide: 7.067%, iron sesquioxide: 0.1%), Colorcon Japan LLC) per tablet, and then a small amount of carnauba wax was added thereto to give film-coated tablets.
- 11.11 g of magnesium stearate was added to 1988.89 g of maleate of Compound A and the mixture was mixed for 30 minutes. The mixed powder was compression-molded by a roller compactor, and the solid obtained by molding was granulated. To 107.13 g of the resulting granulated powder were added 26.21 g of mannitol, 7.50 g of ethyl cellulose (ETHOCEL 100FP Premium, The Dow Chemical Company), 3.75 g of crystalline cellulose (CEOLUS KG-1000, Asahi Kasei Chemicals), 3.75 g of crospovidone (Kollidon CL-SF, BASF) and 0.75 g of croscarmellose sodium, and the mixture was mixed for 30 minutes. 0.90 g of magnesium stearate was added to the mixed powder and the mixture was mixed for 5 minutes. The mixed powder was tableted at a tableting pressure of about 7 kN using a pestle having a double rounded surface with a tablet diameter of 8.5 mm to obtain round uncoated tablets each weighing 315 mg. The uncoated tablets were coated with 9 mg of a coating agent per tablet, and then a small amount of carnauba wax was added thereto to give film-coated tablets.
Claims (1)
1. A method of reducing the amount of amyloid β protein in the brain, comprising administering 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof to a patient,
wherein the amount of amyloid β protein in cerebrospinal fluid is increased by the administration of 1-3(2-1-Benzothiophen-5-yl)ethoxy)propyl)azetidine-3-ol or a salt thereof and the amount of amyloid β protein in the brain is reduced; and
the patient is a patient with an MMSE score of 12 to 22.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/116,914 US20230310371A1 (en) | 2017-06-02 | 2023-03-03 | Agent for reducing amount of amyloid b protein |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017109886 | 2017-06-02 | ||
JP2017-109886 | 2017-06-02 | ||
JP2017-128474 | 2017-06-30 | ||
JP2017128474 | 2017-06-30 | ||
PCT/JP2018/021226 WO2018221732A1 (en) | 2017-06-02 | 2018-06-01 | AMYLOID-β PROTEIN LEVEL DECREASING AGENT |
US201916617607A | 2019-11-27 | 2019-11-27 | |
US18/116,914 US20230310371A1 (en) | 2017-06-02 | 2023-03-03 | Agent for reducing amount of amyloid b protein |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/617,607 Continuation US11666551B2 (en) | 2017-06-02 | 2018-06-01 | Agent for reducing amount of amyloid β protein |
PCT/JP2018/021226 Continuation WO2018221732A1 (en) | 2017-06-02 | 2018-06-01 | AMYLOID-β PROTEIN LEVEL DECREASING AGENT |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230310371A1 true US20230310371A1 (en) | 2023-10-05 |
Family
ID=64455735
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/617,607 Active US11666551B2 (en) | 2017-06-02 | 2018-06-01 | Agent for reducing amount of amyloid β protein |
US18/116,914 Abandoned US20230310371A1 (en) | 2017-06-02 | 2023-03-03 | Agent for reducing amount of amyloid b protein |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/617,607 Active US11666551B2 (en) | 2017-06-02 | 2018-06-01 | Agent for reducing amount of amyloid β protein |
Country Status (14)
Country | Link |
---|---|
US (2) | US11666551B2 (en) |
EP (1) | EP3632429A4 (en) |
JP (1) | JP7256118B2 (en) |
KR (1) | KR20200003102A (en) |
CN (1) | CN110691595A (en) |
AU (1) | AU2018277983B2 (en) |
BR (1) | BR112019024983A2 (en) |
CA (1) | CA3067458C (en) |
IL (1) | IL270914A (en) |
MX (1) | MX2019014306A (en) |
RU (1) | RU2019138538A (en) |
SG (1) | SG11201911519UA (en) |
WO (1) | WO2018221732A1 (en) |
ZA (1) | ZA201907976B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110691593B (en) | 2017-06-02 | 2023-05-02 | 富士胶片富山化学株式会社 | Preventive or therapeutic agent for spinocerebellar degeneration |
JP7282028B2 (en) | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | Cerebral atrophy preventive or therapeutic agent |
EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | Agent for preventing or treating alzheimer-type dementia |
WO2019088083A1 (en) | 2017-10-30 | 2019-05-09 | 富士フイルム富山化学株式会社 | Emopamil binding protein binding agent and use thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001514024A (en) | 1997-09-05 | 2001-09-11 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 50 human secreted proteins |
GB9824207D0 (en) | 1998-11-04 | 1998-12-30 | Zeneca Ltd | Neurological disorders |
PT1437353E (en) | 2001-10-19 | 2007-08-28 | Toyama Chemical Co Ltd | Alkyl ether derivatives or salts thereof |
ES2685923T3 (en) | 2002-06-14 | 2018-10-15 | Toyama Chemical Co., Ltd. | Medicinal composition to improve brain function |
US20060205709A1 (en) | 2003-04-17 | 2006-09-14 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
PL2011796T3 (en) | 2006-04-26 | 2015-03-31 | Toyama Chemical Co Ltd | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
ES2550367T3 (en) | 2008-03-04 | 2015-11-06 | Vernalis (R&D) Ltd. | Azetidine derivatives |
FR2934596B1 (en) | 2008-07-30 | 2015-04-10 | Trophos | NOVEL CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND PROCESS FOR PREPARING THE SAME |
WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
IN2014DN06995A (en) | 2012-02-22 | 2015-04-10 | Toyama Chemical Co Ltd | |
JP6397407B2 (en) | 2012-07-19 | 2018-09-26 | ドレクセル ユニバーシティ | Sigma receptor ligands for modulating cellular protein homeostasis |
CA2882525A1 (en) | 2012-10-01 | 2014-04-10 | F. Hoffman-La Roche Ag | Benzimidazoles as cns active agents |
JP5837726B1 (en) | 2014-01-31 | 2015-12-24 | 富山化学工業株式会社 | Rehabilitation effect promoter after nerve injury containing alkyl ether derivative or salt thereof |
WO2015163318A1 (en) | 2014-04-25 | 2015-10-29 | レジリオ株式会社 | Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease |
WO2015188368A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
WO2016051799A1 (en) | 2014-10-01 | 2016-04-07 | 学校法人同志社 | 2-aminohydroquinone derivative and tau aggregation inhibitor |
SG11201705727TA (en) | 2015-02-02 | 2017-08-30 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
US20160324851A1 (en) | 2015-05-07 | 2016-11-10 | Axovant Sciences, Ltd. | Methods of treating a neurodegenerative disease |
JP6761413B2 (en) | 2015-06-11 | 2020-09-23 | 富士フイルム富山化学株式会社 | Sigma receptor binder |
RU2733404C2 (en) | 2015-12-25 | 2020-10-01 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Pill containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or its salts |
CN110691593B (en) | 2017-06-02 | 2023-05-02 | 富士胶片富山化学株式会社 | Preventive or therapeutic agent for spinocerebellar degeneration |
JP7282028B2 (en) | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | Cerebral atrophy preventive or therapeutic agent |
CN110691594A (en) * | 2017-06-02 | 2020-01-14 | 富士胶片富山化学株式会社 | Preventive or therapeutic agent for tauopathy |
EP3636262A4 (en) * | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | Agent for preventing or treating alzheimer-type dementia |
WO2019088083A1 (en) | 2017-10-30 | 2019-05-09 | 富士フイルム富山化学株式会社 | Emopamil binding protein binding agent and use thereof |
-
2018
- 2018-06-01 US US16/617,607 patent/US11666551B2/en active Active
- 2018-06-01 KR KR1020197035350A patent/KR20200003102A/en not_active IP Right Cessation
- 2018-06-01 RU RU2019138538A patent/RU2019138538A/en unknown
- 2018-06-01 EP EP18809110.2A patent/EP3632429A4/en not_active Withdrawn
- 2018-06-01 JP JP2019521351A patent/JP7256118B2/en active Active
- 2018-06-01 MX MX2019014306A patent/MX2019014306A/en unknown
- 2018-06-01 AU AU2018277983A patent/AU2018277983B2/en active Active
- 2018-06-01 CN CN201880035521.7A patent/CN110691595A/en active Pending
- 2018-06-01 CA CA3067458A patent/CA3067458C/en active Active
- 2018-06-01 SG SG11201911519UA patent/SG11201911519UA/en unknown
- 2018-06-01 WO PCT/JP2018/021226 patent/WO2018221732A1/en active Application Filing
- 2018-06-01 BR BR112019024983-4A patent/BR112019024983A2/en active Search and Examination
-
2019
- 2019-11-25 IL IL270914A patent/IL270914A/en unknown
- 2019-11-29 ZA ZA2019/07976A patent/ZA201907976B/en unknown
-
2023
- 2023-03-03 US US18/116,914 patent/US20230310371A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20200003102A (en) | 2020-01-08 |
MX2019014306A (en) | 2022-06-09 |
RU2019138538A (en) | 2021-07-09 |
WO2018221732A1 (en) | 2018-12-06 |
CA3067458C (en) | 2022-11-01 |
ZA201907976B (en) | 2021-08-25 |
JPWO2018221732A1 (en) | 2020-04-02 |
EP3632429A1 (en) | 2020-04-08 |
US11666551B2 (en) | 2023-06-06 |
CA3067458A1 (en) | 2018-12-06 |
AU2018277983B2 (en) | 2021-04-08 |
IL270914A (en) | 2020-01-30 |
US20210137880A1 (en) | 2021-05-13 |
CN110691595A (en) | 2020-01-14 |
JP7256118B2 (en) | 2023-04-11 |
EP3632429A4 (en) | 2020-06-10 |
RU2019138538A3 (en) | 2021-07-09 |
SG11201911519UA (en) | 2020-01-30 |
BR112019024983A2 (en) | 2020-06-23 |
AU2018277983A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230346745A1 (en) | Agent for preventing or treating tauopathy | |
US20230310371A1 (en) | Agent for reducing amount of amyloid b protein | |
US11951092B2 (en) | Agent for preventing or treating brain atrophy | |
US11541033B2 (en) | Agent for preventing or treating Alzheimer's disease | |
US11660287B2 (en) | Agent for preventing or treating spinocerebellar ataxia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |